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The use of celecoxib is associated with a signiﬁcant decrease in breast cancer risk. However, the long-term use of high-dose
celecoxib might be limited owing to cardiovascular side effects. In this study, we found that acetylbritannilactone (ABL), extract
from a Chinese medicinal herb, could reduce celecoxib dose and potentiate the growth-inhibitory effect in breast cancer cells.
ABL enhanced the apoptotic effect of celecoxib in COX-2-expressing cells, but had little effect in COX-2-negative cells. The
apoptosis induced by the combination treatment disappeared when COX-2 was knocked down, whereas the lack of apoptotic
effects in COX-2-negative cells was reversed after COX-2 transfection. However, the combination treatment induced a G0/G1
phase arrest independent of whether or not the cells expressed COX-2. The G0/G1 arrest was attributed to a decreased
expression of cyclinD1, cyclinE, CDK2 and CDK6, especially the upregulation of p21. In addition, inhibition of Akt and p38
signalingpathwayswasrequiredbythesynergism,astheconstitutivelyactiveAktandp38protectedcellsagainstapoptosisand
cellcyclearrest inducedbythe combinationtreatment.Invivo,administration ofcelecoxibandABLweremoreeffective thanthe
individual agents against xenograft tumor growth. Thus, our data suggested that the combinatorial approach of celecoxib and
ABL might be helpful for breast cancer treatment.
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Breast cancer is the most common cancer among women in
both developed and underdeveloped countries. Abnormally
elevated expression of cyclooxygenase-2 (COX-2) has been
frequently observed in breast cancer tissues and some
researches support the concept that COX-2 could provide
an early target for breast cancer prevention.
1–3 Previous
studies demonstrated that administration of non-steroidal
anti-inﬂammatory drugs (NSAIDs), such as aspirin, ibuprofen,
naproxen, piroxicam or indomethacin, had signiﬁcant chemo-
preventive effects against the development of breast
cancer.
4,5 On the contrary, the long-term use of them may
belimitedowingtoseriousadverseeffectsamongusers,such
as ulcer complications, bleeding, cardiovascular toxicity,
platelet dysfunctions and renal toxicity,
6,7 as a result of
interference of COX-1-derived homeostatic functions. There-
fore, it is rational to search for speciﬁc inhibitors of COX-2 as
potential candidates for use as chemopreventive agents.
Celecoxib, the ﬁrst selective COX-2 inhibitor approved by the
U.S. Food and Drug Administration, is a widely marketed anti-
inﬂammatory drug with improved safety unlike traditional
NSAIDs
8andexertspotentanticancereffectsinvarioustumor
types, including the colon, skin, prostate, lung and breast.
9–14
However, the exact molecular mechanisms involved are not
yet deﬁned. Many lines of evidence from in vitro studies and
animal models indicated that celecoxib exerted its effect by
preventing COX-2 protein expression and prostaglandin E2
(PGE2) synthesis.
9,10 Moreover, other studies suggested that
celecoxib might suppress cell proliferation and carcino-
genesis by downregulating multidrug resistance-associated
protein expression
12 or inhibiting nuclear factor-kappa B
(NF-kB) activation.
13,15
The development of a regimen consisting of a phytochem-
ical with chemopreventive activity combined with celecoxib
would be highly desirable for the treatment of cancer, which
will reduce the dose of celecoxib
16,17 and may minimize dose-
related cardiovascular side effects.
18–20 Acetylbritannilactone
(ABL), a new active extract isolated from a traditional Chinese
medicinal herb Inula britannica L,
21 is commonly used to treat
bronchitis and inﬂammation in China. Previous studies have
shown that ABL exhibit potent anti-inﬂammatory effects in
vascular smooth muscle cells
21–23 and anticancer activities
against colon, breast, ovary, leukemia and prostate cancer
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24–27 Moreover, additional researches reported that ABL
could activate caspases via the mitochondrial apoptosis
pathway, induce Bcl-2 phosphorylation and suppress NF-kB
activation in several types of cell lines.
21,25,27 Therefore, it is
interesting to investigate whether ABL could be a synergist to
help increase the efﬁcacy of other chemopreventive agents in
cancer therapy. With the goal of enhancing the chemo-
preventive effects of celecoxib and reduced the dose
in chemotherapy, we evaluated the possibility of the combina-
tion treatment of celecoxib and ABL on human breast cancer
in vivo and in vitro.
Results
The combination treatment of celecoxib and ABL on
human breast cancer cell growth. The effects of
celecoxib, ABL and their combination on cell growth were
assessed by cell counting assays. Three cell lines (MDA-MB-
231, MDA-MB-468 and MCF-7) that differ in the COX-2
status (Supplementary Figure S1A) were used to elucidate
whether the effects depend on COX-2 expression levels. As
shown in Figure 1a, both celecoxib and ABL suppressed cell
growth in a dose dependent manner. At the doses tested,
neither celecoxib (5mM) nor ABL (25 or 50mM) elicited the
growth-inhibition effect as a single agent, but the combination
treatment signiﬁcantly suppressed cell growth in all three cell
lines. Despite the higher basal level of COX-2 expression in
MDA-MB-231 cells, a comparable degree of growth inhibition
was observed in the other cell lines, which were not found to
differ signiﬁcantly according to COX-2 expression levels. In
the presence of 50mM ABL, IC50 of celecoxib was 4.6mM, a
7.5-fold lower dose than the IC50 (34.4mM) of celecoxib alone
in MDA-MB-231 cells, suggesting that ABL may enhance the
sensitivity of cancer cells to celecoxib. Moreover, there was a
dose-response reduction in MDA-MB-231 cell growth caused
by the combination treatment (Supplementary Figure S1B).
To do mathematical analysis by the median effect method,
MDA-MB-231 cells were treated with both celecoxib and ABL
simultaneously at ﬁxed 1: 5 and 1:10 dose ratio for 48 h.
Combination index (CI) values were calculated as described
previously.
28 As shown in Figure 1b, the CI values of the
concentration were less than 1, indicating that ABL synergis-
tically enhances celecoxib-induced growth inhibition in MDA-
MB-231 cells. Moreover, similar results were obtained in
MDA-MB-468 and MCF-7 cell lines (Supplementary Figure
S1C). Thus, celecoxib and ABL may be an effective
combination for cell growth inhibition due to their synergistic
efﬁcacy.
ABL synergistically enhanced celecoxib-induced
apoptosis. To evaluate the mechanism for synergistic
cytotoxicity between celecoxib and ABL, the extent of
apoptosis was assessed using ELISA. In MDA-MB-231
cells, the formation of cytoplasmic histone-associated DNA
fragments was observed only when they were exposed to the
combination (Figure 2a). DAPI staining assay conﬁrmed the
results (Supplementary Figure S2A). However, a very weak
effect was seen in MCF-7 cells that expressed no constitutive
COX-2 (Figure 2a and Supplementary Figure S2A). Various
ABL doses were tested in the MDA-MB-468 cells, but we
were unable to detect any apoptotic enhancement effect of
celecoxib (5mM) (Supplementary Figure S2B).
Moreover, apoptosis markers were analyzed by western
blot. The combination treatment, instead of individual agents,
resulted in marked increased cleavage of PARP in MDA-MB-
231 cells and, to a minor degree, in MCF-7 cells (Supple-
mentary Figure S2C). Further experiments indicated that the
combination treatment increased the active form of cleaved
caspase-3 and cleaved caspase-9 in MDA-MB-231 cells. The
absence of caspase-3 activation in MCF-7 cells
29 raised the
possibility that the combination treatment might induce
apoptosis through other caspases or death receptor pathways.
Figure 1 Effects of celecoxib, ABL or their combination on the growth of breast cancer cells. (a) Cells were treated with different doses of celecoxib, ABL or their
combination for 48h, and growth inhibition was measured by cell counting assays. The data were showed as the percentage of vehicle-treated cells. Results were expressed
asmean±S.E.M.*Po0.05,comparedwithvehicle-treatedgroup.(b)MDA-MB-231 cellsweretreatedwithcelecoxib(2.5–10mM)plusABL(12.5–100mM)ataﬁxedratioof
1:5 or 1:10, and then the CI was calculated as described in Materials and Methods
ABL is a potent synergist of celecoxib
B Liu et al
2
Cell Death and DiseaseThe combination-induced apoptosis via a COX-2-dependent
manner. To determine whether the combination-induced
apoptosis occurs in a COX-2-dependent route, COX-2
knocked-down cells (KD), which transfected COX-2 siRNA,
and its mock control cells (Control) were established from
MDA-MB-231 cells. The COX-2 expression was markedly
reduced in the KD compared with MDA-MB-231 cells,
whereas we observed no changes in the Control
(Supplementary Figure S3A). PGE2 is a primary product of
the COX-2 enzyme, which represents COX-2 activity. PGE2
production of the Control cells was comparable to that in
MDA-MB-231 cells. However, PGE2 production in the KD
was noted to have decreased to 5% that observed in MDA-
MB-231 cells or the Control (Supplementary Figure S3A).
Moreover, the combination-induced apoptosis were
observed in the Control, but these effects disappeared in
the KD (Figure 2b).
Furthermore, additional experiments were performed to
determine whether the weak apoptotic induction by combina-
tion treatment in MCF-7 cells could be reversed via COX-2
overexpression. For this, we constructed stably transfected
MCF-7 cells (MCF-7-COX-2) and mock control cells (MCF-7-
mock) as previously described.
30 The MCF-7-COX-2 cells
exhibited high expression of COX-2 protein, comparable to
that of MDA-MB-231 cells, whereas the MCF-7-mock cells
expressed no COX-2 (Supplementary Figure S3B). As shown
in Figure 2c, MCF-7-COX-2 cells were more sensitive to
combination treatment than MCF-7-mock cells. Moreover,
TPA (0.1mM)-stimulated MCF-7 cells were treated with the
combination and showed that there was additive proapoptotic
effect in the cells (Figure 2c). In addition, exogenous PGE2
partially prevented the combination-induced apoptosis in
MDA-MB-231 and MCF-7-COX-2 cells (Supplementary
Figure S3C), suggesting that these effects at least partially
suppress PGE2 generation.
ABL synergistically improved the effects of celecoxib on
COX-2 expression and activity. To determine whether the
synergistic effects observed in COX-2 expressing cells were
related to COX-2 synthesis, expression of COX-2 mRNA and
protein was examined in MDA-MB-231 cells. As shown in
Figure 3a, COX-2 was slightly decreased by the single agent,
but was markedly decreased by the combination treatment,
although COX-1 was not changed under the same treatment
conditions. The combination treatment also notably
decreased PGE2 in medium collected from the cells
(Figure 3b). Consistent with western blot results, the
combination treatment on MDA-MB-231 cells led to a
drastic decrease in cytoplasmic COX-2, and COX-1
expression was not affected in immunoﬂuorescence
staining analyses (Supplementary Figure S4A).
Moreover, luciferase-reporter construct containing a frag-
ment of COX-2 promoter was transfected into MCF-7 cells,
which was used to study regulation of COX-2 transcriptional
activity.
31,32 It showed that ABL potentiated the inhibitory
effect of celecoxib on COX-2 activity (Supplementary
Figure S4B). In addition, TPA-induced COX-2 expression
was also markedly suppressed by the combination treatment
(Supplementary Figure S4C).
The combination-induced cell growth inhibition is
mediated partly through G0/G1 arrest. As cell growth
suppression often occurs as a consequence of cell cycle
block, we were interested in knowing whether the effects of
Figure 2 Effects of celecoxib, ABL or their combinations on the apoptosis of breast cancer cells. Cells were treated with celecoxib, ABL or their combination as indicated
for 48h. (a) DNA fragmentation of apoptotic cells was evaluated using a Cell Death Detection ELISA
Plus kit. *Po0.05, compared with vehicle-treated cells. (b) Apoptotic cells
were evaluated by ELISA in Control and KD cells after the combination treatment. Control, MDA-MB-231 cells transfected with a general negative sequence of siRNA;
KD, COX-2 KD MDA-MB-231 cells. (c) MCF-7-mock, MCF-7-COX-2 and TPA (0.1mM)-stimulated MCF-7 cells were treated with combination of celecoxib and ABL for
48 h, and apoptotic cells were evaluated. Results were expressed as mean±S.E.M. from at least three independent experiments
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Cell Death and Diseasethe combination treatment were related to cell cycle
regulation. As determined by ﬂow cytometry, the
combination of celecoxib and ABL induced a signiﬁcant
inhibition of cell cycle progression from the G0/G1 to S phase
in both MDA-MB-231 and MCF-7 cells (Figure 4a). Moreover,
a marked reduction of cyclinD1 and cyclinE expression was
observed when cells were treated with the combination
(Figure 4b). CDK2 and CDK6 levels also decreased.
Conversely, expression of p21 was signiﬁcantly induced
after the combination treatment. In addition, other tested cell
lines treated with celecoxib and ABL also exhibited
considerably increased rates of G0/G1 phase cells (for
Control, KD, MCF-7-COX-2, MCF-7-mock and MDA-MB-
468 cells, respectively), and supplementation with PGE2
(50–200 pg/ml) did not affect the G0/G1 block (Supplementary
Figure S5A). As p21 has a critical role in mediating G0/G1
arrest, we performed experiments to examine whether
overexpression of COX-2 would alter its expression. As
shown in Supplementary Figure S5B, although the COX-2
protein was induced in MCF-7-COX-2 and TPA-stimulated
MCF-7 cells, p21 level was not altered after the combination
treatment. Thus, the results suggested that the combination-
induced cell growth inhibition was mediated, at least in part,
through G0/G1-cell cycle arrest, which was independent of
whether the cells expressed COX-2 or not.
The combination-induced cell growth inhibition
associated with Akt and p38 signaling. To investigate
the common mechanistic basis of apoptosis and cell cycle
arrest for the synergistic effects between celecoxib and ABL,
we determined the changes on the survival signaling
pathways represented by Akt, and also the mitogen-
activated protein kinases cascades.
33 Western blot analysis
showed that exposure of MCF-7 cells to celecoxib or ABL
alone for 2 h resulted in a slight decrease in Akt and p38
phosphorylation induced by TPA (Figure 5a). However, the
combination treatment reduced active Akt and p38 to a
greater degree versus either agent alone. In addition,
combined exposure of cells to celecoxib and ABL resulted
in a modest but discernible decline in the phosphorylation of
downstream Akt target GSK-3b. In contrast, JNK and ERK1/2
activation were barely affected (Figure 5a), suggesting that
they were unlikely to be involved in these processes.
Focusing on Akt and p38, modulation of these pathways
was not cell line speciﬁc, as similar results were observed in
MDA-MB-231 cells after combination treatment.
To address the question on whether the observed changes
in signaling were responsible for the apoptosis, MCF-7 cells
were transfected with Ca-Akt or MKK6b vectors. It showed
that Ca-Akt or MKK6b protected cells from combination-
induced apoptosis, whereas inhibition of these pathways
enhancedpro-apoptoticeffects(Figure5b).Moreover,MCF-7
cells were transfected with COX-2-Luc along with Ca-Akt or
MKK6b vectors and it could restore the TPA-induced COX-2
activity after the combination treatment (Supplementary
Figure S6A). Further works were addressed to evaluate the
ability of celecoxib plus ABL on COX-2 mRNA decay, and
similar effects were observed (Supplementary Figure S6B).
Figure3 EffectsofthecombinationofcelecoxibandABLonCOX-2expressionandactivityinMDA-MD-231cells.(a)MDA-MD-231cellsweretreatedwithcelecoxib,ABL
or their combination for 24h (left) or 48h (right). COX-2 mRNA and protein expression was examined using RT-PCR (left) and western blot analysis (right). Quantiﬁcation of
COX-2 mRNA and protein expression normalized to actin levels, were provided at the bottom. (b) MDA-MB-231 cells were treated with the combination for 48h, and PGE2
levels in the culture medium were measured using ELISA. Results were expressed as mean±S.E.M. from at least three independent experiments
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Cell Death and DiseaseThese results indicated that the combination treatment
modulated the activation of Akt and p38, beyond the primary
effect on COX-2.
Subsequently, the roles of the above signal pathways were
determined in cell cycle regulation. As shown in Figure 5c,
activation of the Akt or p38 pathway signiﬁcantly decreased
cell number in G0/G1 phase, whereas inhibition of these
pathways enhanced cell G0/G1 cycle arrest by the combina-
tion treatment. Thus, it indicated that the synergism reﬂected
inhibition of Akt and p38 that occurred upstream of combina-
tion-initiated cell cycle arrest.
Therapeutic effects of combination treatment against
MDA-MB-231 xenograft model. As the combination
treatment of celecoxib and ABL was more effective than
the individual agents in vitro, effects of them on tumor
development were examined in athymic nude mice. As
shown in Figure 6a, treatment with celecoxib (5mg/kg) or
ABL (15mg/kg) had weak inhibitory effect on MDA-MB-231
tumor growth, whereas the combination treatment
signiﬁcantly reduced tumor volume by 50% (Po0.05)
after 30 days. All the groups were well tolerated without
obvious signs of drug-related toxicity throughout the course
of this study.
Furthermore, the COX-2 expression at tumor specimens
was measured. Compared with the individual use of one
agent, it clearly indicated that tumor specimens from
celecoxibplus ABL-treatedmicestained moreweaklypositive
COX-2 expression (Supplementary Figure S7A). Similar
results were also determined by western blot analysis in
protein extracted from the tumor tissue (Figure 6b). The
ﬁndings from ELISA assay for serum PGE2 level showed a
signiﬁcant decrease in mice that received the combination
treatment (Supplementary Figure S7B). Further, in-depth
analysis indicated a positive correlation between the serum
PGE2 level and tumor COX-2 expression (Pearson’s correla-
tion coefﬁcient, 0.900; Po0.001, two-tailed) (Figure 6c).
Moreover, augmented expression of p21 and marked
increased cleavage of PARP (Figure 6b) was evident in the
mice that received the combination treatment, conﬁrming
in vitro data.
We ﬁnally evaluated whether the effects of the combination
treatment on signal transduction could be also observed
in vivo. As shown in Figure 6b, although the inhibitory effects
exerted by the individual agents were mild, total and
phosphorylated Akt and p38 were downregulated among the
mice that received the combination treatment.
Discussion
In this study, we found that the phytochemical ABL synergis-
tically augmented the growth-inhibitory effects of celecoxib on
breast cancer cells via COX-2-dependent apoptosis and
COX-2-independent cell cycle regulation involving Akt and
p38 pathways. Moreover, the therapeutic potential of this
combination was shown in its superior activity in suppressing
the xenograft tumor growth comparing with that of individual
agents.
The combinatorial strategies in cancer therapies can
provide more synergistic tumor inhibition and less systemic
toxicity than each of the monotherapeutic regimens alone.
34–36
Current results showed that ABL was useful to increase the
anticancer activity of celecoxib and reduce its dose. Low dose of
celecoxib (5mM) plus ABL (50mM) was sufﬁcient to suppress
breast cancer cell growth in vitro. This effect was more than that
exerted by a higher dose of celecoxib (440mM) when
administered alone. The dose of celecoxib using here was lower
than clinically achievable plasma levels.
37 It might be clinically
useful, because it could be achieved in the patients who receive
the standard dose of celecoxib to cure the neoplastic disease
and also avoids the related cardiovascular risk.
18–20 Moreover,
we found that ABL primarily affects the sensitization of COX-2-
expressing cells to celecoxib and does not tend to confer this
sensitivity to COX-2-nonexpressing cells. Thus, it would be
reasonable to suppose that ABL-augmented celecoxib-
induced apoptosis occurs via a COX-2-dependent mechanism.
Figure 4 Effects of the combination of celecoxib and ABL on cell cycle
progression. (a) MDA-MB-231 and MCF-7 cells were treated with celecoxib, ABL
alone or their combination for 24h. Cell cycle distributions were determined by ﬂow
cytometry analysis. The bar graph reﬂected the percentage of cells in G0/G1,S ,G 2/M
phase of cell cycle. (b) Cells were treated with the combination for 24h and
subjected to western blot with speciﬁc antibodies directed against cyclin D1, cyclin
E, CDK-2, CDK-4, CDK-6, p21 and p27. Densitometric analyses of western
blot, normalized to actin levels, were provided. Each column represents the
mean±S.E.M.
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Cell Death and DiseaseFigure5 EffectsofthecombinationofcelecoxibandABLonsignalingpathwaysinMCF-7cells.(a)MCF-7cellswerecotreatedwithTPAandthecombinationfor2h,then
celllysateswereanalyzedbywesternblotforp-Akt,p-GSK-3b,p-p38,p-JNKandp-ERK1/2.Densitometricanalysesofwesternblot,normalizedtoactinlevels,wereprovided.
(b) MCF-7 cells were transfected with the Ca-Akt or MKK6b vector and then treated with TAP and the combinationin the presence of Akt inhibitor (LY294002) or p38 inhibitor
(SB203580) for 48h as indicated. The percentage of apoptotic cells was determined by ELISA. (c) The transfected cells were treated with the combination in the presence of
LY294002 or SB203580 for 24h. Cell cycle distribution was analyzed by ﬂow cytometry. Results were expressed as mean±S.E.M.
Figure 6 Effects of celecoxib and ABL individually and in combination on MDA-MB-231 Xenograft model. Female nude mice bearing MDA-MB-231 tumors were treated
withvehicle,celecoxib(5mg/kg)andABL (15mg/kg)individually,orin combination. (a)Tumorsweremeasuredwithcalipersonalternatedays.Points, meantumorvolumein
eachexperimentalgroupcontainingsixmice.*Po0.01versusvehiclegroup.(b)TheexpressionofCOX-2,COX-1,p21,PARP,p-Akt,Akt,p-p38andp38weredeterminedby
western blot analysis in protein extracted from the tumor specimens. Total protein samples from two mice for each group representing control and experiment were used for
western blot. Densitometric analyses of western blot (average of two samples) were provided. Each column represents the mean±S.E.M. (c) A strong positive correlation
(data shown were obtained from Supplementary Figure S7A and B) between serum PGE2 level and COX-2 expression in xenograft specimens (Pearson’s correlation
coefﬁcient, 0.900; Po0.001, two-tailed)
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Cell Death and DiseaseFurthermore, we observed that only the combination treatment
decreased COX-2 expression, activity and notably reduced
PGE2 production in COX-2-overexpressing cells. It can be
inferred that the synergistic effects may be not only mediated by
COX-2proteinitselforbysubstratesorenzymesintheupstream
regions of this protein, but also by its end product. In addition, the
combination treatment has no effect on COX-1 expression
in vitro and in vivo experiment, it is reasonable to assume that it
may be avoid of the side effects associated with the suppression
of COX-1-derived prostanoids.
ManystudieshaveshowedthatCOX-2mightbeassociated
with drug resistance. Several treatment, such as paclitaxel,
38
mitomycin C,
39 and radiation therapy,
40 induced COX-2
overexpression, resulting in some adverse effects associated
with inﬂammation, angiogenesis, invasion and meta-
stasis.
1,10,41 Therefore, downregulation of COX-2 expression
might provide effective approaches to treat cancer patients
who were sufferings drug resistance. Previous studies
showed that the prototype tumor promoter TPA induced
COX-2 expression in MCF-7 cells by activating transcription
factors such as NF-kB and activator protein-1 (AP-1).
31,32 In
the present study, we used TAP-induced MCF-7 cells to
simulate the condition of drug resistance related to COX-2
overexpression. Surprisingly, the combination treatment
suppressed COX-2 activation and induced signiﬁcant apop-
tosis in TPA-stimulated MCF-7 cells, suggesting that the
therapeutic regimen might be helpful in drug resistance
related to COX-2 expression.
As cell growth inhibition often occurs as a result of cell cycle
arrest, we determined the second mechanism underlying the
synergistic effects. Previous studies have shown that treat-
ment with low dose of celecoxib (o20mM) alone for a short
time (o72h) may not affect cell viability and cell cycle
distribution.
14,42 Conversely, we found that the combination
treatment of celecoxib (5mM) and ABL (50mM) for 24h
induced G0/G1 arrest in all the tested cells. The incomplete
protection by addition of PGE2 or COX-2 overexpression, and
the fact that overexpression or depletion of COX-2 failed to
alter the cell cycle indicated the existence of COX-2-
independent mechanism. Moreover, the combination-
mediatedcell cyclearrestcouldbecausedbythe suppression
ofcyclinD1,cyclinE,CDK2andCDK6activities,especiallythe
upregulation of p21, which were signiﬁcant and consistent
with the earlier studies that increased p21 expression were
associated with inactive of CDKs/cyclin complexes and
induced of G0/G1 arrest.
43,44
Another important observation in this study was that
celecoxib combined with ABL suppressed phosphorylated
Akt and p38. Activated Akt and p38 targeted multiple factors
involving in cell proliferation, survival and also mediating cell
cycle alteration and apoptosis. Recently, many studies have
demonstrated that the cytotoxic compounds could suppress
cancer cell growth through these signaling pathways. Flavo-
piridol could interfere with Akt and p38 and enhanced cell
apoptosis.
45 Furthermore, Akt and p38 were identiﬁed as key
signaling responsible for paclitaxel in metastatic breast
cancer.
46 In the presence of ABL, celecoxib dramatically
downregulated Akt and p38 pathways so as to facilitate
apoptosis and cell cycle arrest. Thus, we hypothesize that Akt
and p38 signaling represent a therapeutically relevant target
for ABL to sensitize these cells to celecoxib via two potential
mechanisms. First, the suppression of these pathways by the
combination treatment would lead to the inhibition of COX-2
expression and activity, which triggered the apoptosis
regulators to facilitate apoptosis. Second, ABL interacted
synergistically with celecoxib, which could block Akt and p38
activation. Thereby, this process inﬂuenced the cell cycle
regulator proteins and induced G0/G1 phase cell arrest.
In summary, ABL synergistically enhanced the activity of
celecoxib on breast cancer growth inhibition through COX-2-
dependent and COX-2-independent mechanisms. Findings
from this study concluded that the combination treatment of
celecoxib and ABL could improve the chemopreventive
efﬁcacy certainly in breast cancer and help to explain the
anticancer properties of these chemopreventive agents.
Materials and Methods
Reagents, antibodies and plasmids. Celecoxib was provided by LKT
Laboratories, Inc. (Minneapolis, MN, USA). Silica gel column chromatography was
used to isolate ABL from Inula britannica L grown in Shan-xi Province in China. The
effects of ABL and celecoxib in our experiments were compared with the same
concentration of dimethyl sulfoxide (DMSO) as vehicle. The antibodies speciﬁc for
Poly (ADP-ribose) polymerase (PARP), phospho-c-Jun NH2-terminal kinase
(p-JNK), phospho-p38 MAP kinase (p-p38) and p38 were obtained from Cell
Signaling Technology (Beverly, MA, USA). Antibodies against COX-1, COX-2,
b-actin, caspase-3, caspase-9, phospho-extracellular signal-regulated kinase1/2
(p-ERK1/2), phospho-Akt (p-Akt), Akt, phospho-GSK-3b (p-GSK-3b), the
secondary antibodies, small interfering RNA (siRNA) speciﬁc for human COX-2
mRNA and control siRNA were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Unless otherwise indicated, all other reagents used in this study were
obtained from Sigma Chemicals (St. Louis, MO, USA). Constitutively active p38
construct MKK6b was kindly provided by Dr. Han (The Scripps Research Institute,
CA, USA). Constitutively active Akt construct Ca-Akt was gifts from Dr. Woodgett
(Ontario Cancer Institute, Toronto, Canada).
Cell lines and culture conditions. The human breast cancer cell lines
(MDA-MB-231, MDA-MB-468 and MCF-7) were from American Type Culture
Collection (Manassas, VA, USA). Cells were grown in a 5% CO2 atmosphere at
371C in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum. All treatments were carried out on cells at 60–80% conﬂuence.
Cell growth inhibition assays. The cells were plated in duplicatein 12-well
plates. After 24h, celecoxib, ABL and their combination were added at the selected
doses to the culture medium. The number of viable cells was determined by a
Coulter counter 48 h later. We calculated the IC50 by using a standard sigmoidal
Emaxmodel. Todeterminewhetherthecombinedeffectsweresynergistic,thecells
were treated with the combination of the indicated doses of celecoxib and ABL for
48 h and the CI was determined using the method of Chou and Talalay through the
commercial software package Calcusyn (Biosoft, Cambridge, UK).
28
Apoptosis assays. Apoptosis was determined by two independent
methods.
47 For ﬂuorescence microscopy, cells were treated with agents for 48h.
Apoptoticcells weredetectedbynuclear morphologic changesusingDAPI staining.
Cells were harvested, washed with PBS and ﬁxed in 70% ethanol for 30min. The
ﬁxed cells were placed on slides and stained with 1mg/ml DAPI for 15min. Excess
dyewasremovedandthemonolayerwasthoroughlywashedwithPBS.Thestained
nuclei were observed via a ﬂuorescence microscope.
For ELISA, the cells seeded in 96-well plates were treated with agents for
48 h. The induction of apoptosis by the agents was evaluated with a Cell Death
Detection ELISA
Plus kit (Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instruction. Measurements were made using an ELISA reader at
405nmandtheresultswerecalculatedastheratiooftheabsorbanceoftheagents-
treated cells/absorbance of vehicle-treated cells.
Cell cycle analysis. Cells were treated with agents at selected doses and
harvested by trypsinization, washed with PBS, ﬁxed with ethanol, incubated for
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25mg/ml RNase. Stained cells were analyzed by ﬂow cytometry (Becton Dickinson,
San Jose, CA, USA).
Immunohistochemistry. Parafﬁn-embedded tumor specimens were
subjected to immunohistochemistry according to the antibody protocol.
Specimens were developed using secondary antibodies linked to HRP and DBA
as a substrate.
Immunoﬂuorescence microscopy. Cells were treated with agents at
selected doses for 48h, then ﬁxed on coverslips with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100 and blocked in 5% goat serum, and then
incubated overnight at 41C with antibodies, followed by incubation with FITC-
conjugated secondary antibody for 1h at room temperature in the dark. Nuclear
counterstaining was performed with PI for 10min at room temperature.
Fluorescence was visualized under a ﬂuorescence microscope (Olympus, Tokyo,
Japan).
Reversetranscription-PCR(RT-PCR). TotalRNAwasisolatedfromcells
usingTRIzol Reagent (Invitrogen)and equal amountswere reverse transcribedinto
cDNA using the oligo dT primer, then the cDNAs were used as DNA templates for
PCR. Primers used for COX-2 were 50-TTCAAATGAGATTGTGGGAAAAT-30and
50-AGATCATCTCTGCCTGAGTATCTT-30. b-actin was used to ensure equal
loading. The PCR products were separated on 1% agarose gel and visualized by
ethidium bromide.
Western blot analysis. Equal amounts of proteins were subjected to SDS-
PAGE analysis and subsequent immunoblotting was carried out with speciﬁc
antibodies. Levels of immunocomplexes for b-actin were used as an internal
standardforequalloading.Allexperimentswererepeatedatleastthriceandyielded
similar results.
PGE2 production. PGE2 from the collected cell medium or the animal serum
was determined by a commercially available PGE2-speciﬁc ELISA (R&D
Biosystems, Abingdon, UK) according to manufacturer’s instructions.
Transfection of siRNA. siRNAs speciﬁc for COX-2 (COX-2 siRNA) and
control siRNA were transfected into cells using transfection reagent Lipofectamine
2000 (Invitrogen). RT-PCR and western blot were used to conﬁrm adequate
silencing of the COX-2 genes at 48h.
Transfection of cells. Cells were transfected either with empty vector or the
same vector containing a cDNA encoding constitutively active p38 construct
MKK6b, constitutively active Akt construct Ca-Akt.
The stably transfected cells were conducted using COX-2 expression plasmid
(full-length human COX-2 cDNA cloned in pcDNA3 vector) and G418 geneticin
(Invitrogen) as described previously.
30 Individual drug-resistant colonies were
isolatedandexpanded.TheselectedcellswithsuccessfuloverexpressionofCOX-2
protein were used for subsequent experiments.
Luciferase assays. The COX-2 luciferase reporter construct (COX-2-Luc)
( 1432/þ59), containing the wild-type COX-2 promoter fragment, was prepared
andclonedintothepGL3basicvector.Cellswereplatedin24-wellplates.Transient
transfections were performed using the transfection reagent Lipofectamine 2000.
Each well was co-transfected with COX-2-Luc plasmid and the internal control
plasmid renilla luciferase (pRL-TK). The cells were harvested after the indicated
times of treatment, and the activities of both ﬁreﬂy luciferase and pRL-TK luciferase
were measured.
Xenograft model. Theanimalstudywasperformedviaaprotocolapprovedby
the governmental committee for animal research. Female BALB/c nude mice (4–5
weeks old) were injected s.c. with MDA-MB-231 cells (6 10
6) per mice at both
ﬂanks and randomly assigned to treatment groups (six mice per group). After 6
days,whenasmall vascularized tumor(50–100mm
3)haddeveloped, controlgroup
was treated with vehicle (10% DMSO, 10% ethanol in water) daily by i.p. injection.
The celecoxib group (5mg/kg) was treateddaily by oral administration as described
previously.
10 ABL group (15mg/kg) was given daily by i.p. injection. The group
treated with the combination was dosed in the same manner as both single-agent
groups. Mice were weighed at least twice a week and the tumor size was measured
every other day using calipers and their volumes were calculated according to a
standardformula:width
2 length/2.Micewerekilledafter36 daysof treatmentand
the tumor specimens were removed for immunohistochemistry and western blot
analysis.
Statistical analysis. All of the experiments were repeateda minimumof three
times. Data were presented as mean±S.E.M. Statistical analyses of the
differences between the groups were determined with the two-sided unpaired
Student’st-testusingSPSSsoftware(SPSS,Inc.,Chicago,IL,USA),andavalueof
Po0.05 was considered as signiﬁcant.
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